Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | EPOR | P19235 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25331006 | 1.00 | GLP1R (0.50) | GLP1RHPGDHTTSMN1; SMN2PTGS1 | |
| SCHEMBL25332367 | 0.94 | GLP1R (0.47) | GLP1RHPGDHTTSMN1; SMN2GLO1 | |
| SCHEMBL25332373 | 0.94 | GLP1R (0.47) | GLP1RHPGDHTTSMN1; SMN2GLO1 | |
| SCHEMBL25330505 | 0.92 | GLP1R (0.45) | GLP1RHPGDHTTSMN1; SMN2 | |
| SCHEMBL25330500 | 0.92 | GLP1R (0.45) | GLP1RHPGDHTTSMN1; SMN2 | |
| SCHEMBL31690610 | 0.91 | GLP1R (0.49) | GLP1RHPGDHTTSMN1; SMN2PTGS1 | |
| SCHEMBL23451315 | 0.90 | GLP1R (0.51) | GLP1RHPGDHTTSMN1; SMN2PTGS1 | |
| SCHEMBL23451314 | 0.90 | GLP1R (0.51) | GLP1RHPGDHTTSMN1; SMN2PTGS1 | |
| SCHEMBL29467662 | 0.90 | GLP1R (0.51) | GLP1RHPGDHTTSMN1; SMN2PTGS1 | |
| SCHEMBL29467661 | 0.89 | GLP1R (0.43) | GLP1RHPGDHTTSMN1; SMN2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | GLP1R 2264/4885HPGD 3435/4885HTT 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.